NEWS
-
MEDIA
-
PRESENTATION
Our CEO, Kohtaro Toda, will present “The Realities of Utilizing a CDMO” at the J-TEC CDMO Seminar (in Japanese)
For more details, please see the link below.
https://www.jpte.co.jp/business/cdmo-cro/columns/details/587 -
NEWS
Leadership Transition
Metcela announces changes in executive leadership as follows.
Read more… -
NEWS
Metcela to Strengthen Clinical Pipeline Development, New Headquarters and R&D Center at Kawasaki King Skyfront
Accelerating the creation and commercialization of drug discovery pipelines through in-house development at King Skyfront, an international strategic base in Tonomachi, Kanagawa Prefecture, where a number of new drug discovery and biotech companies are being establishedRead more…
-
PRESS RELEASE
Metcela and Nagoya University to Collaborate in Research to Accelerate the Development of Regenerative Medicine
Accelerate development of fibroblast-based pipelines in cardiovascular and respiratory disease areasRead more…
-
PRESS RELEASE
Metcela Eligible to Receive up to $7 Million (1 Billion JPY) AMED Grant for Promoting the Development of Regenerative Medicine Product Using Cardiac Stem Cells
Accelerate the Phase III clinical trial of cardiac stem cell-based product for pediatric congenital heart disease patientsRead more…
-
PRESS RELEASE
Metcela Inc. Completes the Series C Financing of Total $14 Million
Total of $14 million (1.87 billion JPY) was raised in the Series C round, and cumulative $35 million (4.6 billion JPY, including grants) has been raised to date. Metcela is aiming to create new therapeutic options for heart failure by establishing an ecosystem for autologous cell therapy.
